Becton, Dickinson and Company (NYSE:BDX) Citi's 2025 Unplugged Medtech and Life Sciences Access Day November 27, 2025 8:45 AM ET Company Participants Tom Polen – Chairman, Chief Executive Officer and President Chris DelOrefice – Executive Vice President and Chief Financial Officer Conference Call Participants Joanne Wuensch – Citi Joanne Wuensch We're live? Excellent. Hi, I'm Joanne Wuensch, I'm the medical technology analyst here at Citibank and we are in Citi's Unplugged Medtech and Life Sciences Tools Da ...

FRANKLIN LAKES, N.J., Feb. 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following healthcare conferences:Citi's 2025 Unplugged Medtech and Life Sciences Access DayFebruary 27, 20258:45 a.m. Eastern TimeBarclays 27th Annual Global Healthcare ConferenceMarch 11, 20258:30 a.m. Eastern TimeThe live webcasts of BD's presentations can be accessed from the BD investor relations website, investors.bd ...

Activist Commentary: Starboard is a very successful activist investor and has extensive experience helping companies focus on operational efficiency and margin improvement. Starboard also has significant experience with its strategic activism. In 57 prior campaigns where it had a strategic thesis, the firm had a 32.96% return versus 14.61% for the Russell 2000 during the same period. Additionally, Starboard has initiated activist campaigns at 24 prior health-care companies and its average return on these si ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-4802 Becton, Dickinson and Company (Exact name of registrant as specified in its charter) New Jersey 22-0760120 (State or oth ...

Financial Data and Key Metrics Changes - The company reported a revenue growth of 9.6%, with organic growth at 3.9% for Q1 2025, exceeding financial goals [11][21] - Adjusted diluted EPS increased by 28% to $3.43, driven by strong operational performance [11][23] - Adjusted gross margin reached 54.8%, and adjusted operating margin was 23.6%, reflecting expansions of 370 and 340 basis points year-over-year, respectively [11][23] Business Line Data and Key Metrics Changes - The MedTech business led organic growth with approximately 5%, driven by volume increases and market share gains across core devices [21] - Diagnostic Solutions experienced modest growth, supported by Lab Automation and BD MAX molecular platform IVD assays, but faced challenges due to respiratory season timing [21] - Biosciences showed an expected decline due to market dynamics and reduced research funding in China and the US [22] Market Data and Key Metrics Changes - Total company organic growth was primarily driven by strong performance in the US, while China experienced a decline, particularly in Biosciences [22] - The company anticipates a translational currency headwind of approximately $250 million for the full fiscal year, impacting revenue guidance [27] Company Strategy and Development Direction - The company announced its intention to separate the Biosciences and Diagnostic Solutions business to enhance strategic focus and drive growth [5][32] - The New BD will focus on being a pure-play MedTech company, while the separated business will aim to be a leader in Life Sciences Tools & Diagnostics [32][41] - The separation is expected to unlock significant value for both entities, allowing for targeted capital deployment and enhanced focus on high-growth areas [32][58] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational performance and affirmed full-year guidance despite currency impacts [12][28] - The company is closely monitoring market dynamics, particularly in China and research funding levels, while maintaining a cautious outlook [26][116] - Management highlighted the strong innovation pipeline and the potential for both New BD and the separated business to thrive in their respective markets [19][32] Other Important Information - The company returned over $1 billion to shareholders in Q1, including $300 million in dividends and a $750 million accelerated share buyback [12][25] - The planned separation will allow the company to focus on executing its BD 2025 strategy and continue investments in innovation and growth [5][57] Q&A Session Summary Question: Why now for the separation and how to manage dissynergies? - Management indicated that the separation is a strategic move to unlock value and enhance focus on high-growth areas, with ongoing monitoring of potential dissynergies [68][69] Question: Impact of tariffs on BD's operations? - Management noted that the largest manufacturing footprint is in North America, and they are monitoring tariff discussions closely, particularly regarding potential carve-outs for medical devices [80] Question: Areas for investment post-separation? - Management emphasized the focus on high-growth accretive opportunities, particularly in the Interventional segment and R&D for new product launches [88][90] Question: Trends in China and research spending? - Management acknowledged a slowdown in research spending impacting performance, particularly in China, but expressed confidence in capitalizing on recovery when it occurs [116][120] Question: EPS guidance and integration of Critical Care? - Management clarified that the operating strength from Q1 is reflected in the updated EPS guidance, and integration efforts are ongoing [134]

Advancing the world of healthTM Caution Concerning Forward-looking Statements This presentation and accompanying webcast contain certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's future prospects and performance, including, but not limited to, future revenues, margins, earnings per share, leverage targets and capital deployment, and the contemplated separation of BD's Biosciences and Diagnostic Solutions business, including, but not limited to, ...

For the quarter ended December 2024, Becton Dickinson (BDX) reported revenue of $5.17 billion, up 9.8% over the same period last year. EPS came in at $3.43, compared to $2.68 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $5.1 billion, representing a surprise of +1.32%. The company delivered an EPS surprise of +15.10%, with the consensus EPS estimate being $2.98.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and h ...

Becton Dickinson (BDX) came out with quarterly earnings of $3.43 per share, beating the Zacks Consensus Estimate of $2.98 per share. This compares to earnings of $2.68 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15.10%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $3.77 per share when it actually produced earnings of $3.81, delivering a surprise of 1.06%.Over the last four qua ...

Revenue Performance - Revenue for Q1 FY2025 was $5.2 billion, representing a 9.8% increase year-over-year, with 9.6% growth on a currency-neutral basis and 3.9% organic growth[4] - BD Medical segment revenue was $2.615 billion, up 17.3%, driven by strong performance in Medication Delivery Solutions[12] - BD Life Sciences segment revenue was $1.297 billion, showing a slight increase of 0.7%[12] - BD Interventional segment revenue reached $1.257 billion, reflecting a 5.8% increase[12] - Revenues for the three months ended December 31, 2024, were $5,168 million, representing a 9.8% increase compared to $4,706 million in the same period of 2023[31] - Total revenues for the three months ended December 31, 2024, were $5,168 million, representing a 9.8% increase compared to $4,706 million in 2023[38] - BD Medical segment revenues increased to $2,615 million, up 17.3% from $2,230 million in the prior year[41] - Organic revenue for BD Medical was $2,343 million, reflecting a 5.1% growth compared to $2,230 million in 2023[41] - BD Life Sciences reported total revenues of $1,297 million, a slight increase of 0.7% from $1,288 million in the previous year[38] Earnings and Guidance - GAAP diluted EPS was $1.04, an increase of 8.3%, while adjusted diluted EPS grew by 28.0% to $3.43[4] - BD increased its FY25 adjusted diluted EPS guidance to a range of $14.30 to $14.60, reflecting a growth of approximately 10% at the midpoint[15] - Reported diluted earnings per share for the three months ended December 31, 2024, were $1.04, an increase of 8.3% from $0.96 in 2023[44] - Adjusted diluted earnings per share rose to $3.43, marking a 28.0% increase from $2.68 in the same period last year[44] - For FY 2025, BD expects reported revenue growth of 7.9% to 8.4%, with organic revenue growth projected at 4.0% to 4.5%[47] - The company anticipates total revenues for FY 2025 to be approximately $21.7 to $21.9 billion[49] Costs and Expenses - Research and development expenses rose by 18.2% to $343 million, compared to $290 million in the previous year[31] - Total operating costs and expenses increased by 10.5% to $4,715 million, up from $4,267 million in the prior year[31] - The company incurred $67 million in accruals impacting revenues due to recent developments related to Italian government medical device payback legislation[54] - A charge of $38 million was recorded to cost of products sold for future product remediation efforts[54] - The company recognized a $175 million charge related to an estimated liability for an SEC investigation concerning reporting issues with BD Alaris infusion pumps[54] - Costs associated with the Advanced Patient Monitoring acquisition included transaction costs recorded in integration and restructuring expenses[52] - Significant costs were incurred to comply with the European Union Medical Device Regulation, categorized as one-off costs limited to a specific period[53] - Integration and restructuring activities resulted in additional costs that impacted overall financial performance[51] - The separation of BD's former Diabetes Care business incurred costs recorded in other operating expenses[52] Cash Flow and Assets - Cash and equivalents decreased to $711 million from $1,717 million at the end of the previous quarter[32] - Total assets decreased to $54,665 million from $57,286 million in the prior quarter[32] - The company generated $693 million in net cash from operating activities, down from $855 million in the same period last year[33] Strategic Initiatives - The company announced plans to separate Biosciences and Diagnostic Solutions to enhance growth and innovation in their respective markets[2] - The BD Onclarity™ HPV Assay was added to the ASCCP guidelines, enhancing its market position in cervical cancer screening[11] - The Advanced Patient Monitoring unit, newly integrated into BD Medical, contributed to the overall revenue growth but was not reported in the previous year[39] Legal and Compliance Issues - Legal matters and asset impairment charges have affected the company's financial results, reflecting unusual operational impacts[54] - The company is focused on developing processes for compliance with new regulatory frameworks, impacting research and development expenses[53] - The company recorded certain income and expense items affecting comparability, including product remediation costs and legal matters[54]

Compelling opportunity expected to unlock substantial value through enhanced focus, tailored investment and capital allocation, and optimized market valuation  "New BD," built on momentum of BD 2025 strategy, will be well-positioned as a scaled, pure-play MedTech leader focused on attractive categories shaping the future of health care Biosciences and Diagnostic Solutions to realize its full market potential as differentiated leader in Life Sciences Tools and Diagnostics, with robust innovation pipeline an ...